Connect
MJA
MJA

Time for the Pharmaceutical Benefits Advisory Committee to set its own agenda

Wendy L Lipworth, Ian Kerridge and Richard O Day
Med J Aust 2012; 196 (6): 374-375. || doi: 10.5694/mja12.10152
Published online: 2 April 2012

Drug subsidy recommendations should be informed by active assessment of current evidence and emerging treatments

Decisions about which medicines should be subsidised by the Australian Government on the Pharmaceutical Benefits Scheme (PBS) are based on recommendations made by the Pharmaceutical Benefits Advisory Committee (PBAC) — an independent statutory body appointed by the government.1

  • Wendy L Lipworth1
  • Ian Kerridge2
  • Richard O Day3

  • 1 Australian Institute of Health Innovation, University of New South Wales, Sydney, NSW.
  • 2 Centre for Values, Ethics and the Law in Medicine, University of Sydney, Sydney, NSW.
  • 3 Clinical Pharmacology and Toxicology, St Vincent's Hospital, Sydney, NSW.

Correspondence: w.lipworth@unsw.edu.au

Competing interests:

No relevant disclosures.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.